Peptides

GLP-1 Peptides: Semaglutide, Tirzepatide, Retatrutide & How They Work

The complete guide to GLP-1 receptor agonist peptides — mechanisms, drug comparisons, side effects, and what's coming next

GLP-1 (glucagon-like peptide-1) is a naturally occurring gut peptide that regulates appetite, blood sugar, and gastric emptying. GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and the in-development retatrutide — are peptide-based drugs producing 15–24% average weight loss in clinical trials. This guide covers how they work, compares current options, and explains what's coming next.

GLP-1 receptor agonists are arguably the most transformative drug class developed in the past decade. Semaglutide alone generated over $13 billion in revenue in 2023 — driven by its unprecedented efficacy for both diabetes management and weight loss. These are peptide-based drugs: small protein chains that mimic the natural gut hormone GLP-1.

GLP-1 is secreted by L-cells in the intestinal wall after eating. Its natural half-life is 1–2 minutes — pharmaceutical versions are engineered to last days to weeks through chemical modifications. Understanding what GLP-1 does naturally makes the drug effects make sense: it suppresses appetite, slows digestion, stimulates insulin release in response to blood glucose, and reduces glucagon (the counter-regulatory hormone that raises blood sugar).

How GLP-1 Peptides Work

GLP-1 receptors are found in the pancreas, brain (hypothalamus, brainstem), stomach, heart, kidneys, and other tissues. Activating these receptors produces multiple coordinated effects:

GLP-1 Drug Comparison

DrugBrand NamesTargetAvg. Weight LossFrequencyStatus
SemaglutideOzempic (diabetes), Wegovy (obesity), Rybelsus (oral)GLP-114.9% (STEP 1)Weekly injectionFDA approved
TirzepatideMounjaro (diabetes), Zepbound (obesity)GIP + GLP-1 (dual)22.5% (SURMOUNT-1)Weekly injectionFDA approved
RetatrutideLY3437943 (Eli Lilly)GIP + GLP-1 + glucagon (triple)24.2% at 48 wks (Phase II)Weekly injectionPhase III trials
OrforglipronEli Lilly oral GLP-1GLP-1 (non-peptide)~15% (Phase II)Daily oral pillPhase III trials
Cagrilintide + semaCagriSemaGLP-1 + amylin~22.7% (Phase III)Weekly injectionPhase III trials
LiraglutideSaxenda (obesity), Victoza (diabetes)GLP-1~8% (SCALE trial)Daily injectionFDA approved (older)

Semaglutide vs. Tirzepatide: Which to Choose

Both are effective — tirzepatide produces roughly 50% more weight loss on average. The key differences:

What's Coming: The Next Generation

Retatrutide (Eli Lilly's triple agonist) showed 24.2% average weight loss at 48 weeks in Phase II — a figure previously seen only with bariatric surgery. Phase III data is expected 2025–2026. If confirmed, it may become the highest-efficacy pharmacological weight-loss option available without surgery.

Oral non-peptide GLP-1 agonists (orforglipron, danuglipron) are in Phase III and could dramatically expand access — eliminating the injection requirement that remains a barrier for some patients. These are small molecules, not peptides, but they activate the same GLP-1 receptor.

Frequently Asked Questions

What is a GLP-1 peptide?

GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone released after eating. It regulates appetite, blood sugar, and digestion. Pharmaceutical GLP-1 receptor agonists (semaglutide, tirzepatide) are synthetic peptide analogs engineered to last much longer than natural GLP-1 (days vs. minutes). They're among the most effective weight-loss medications ever developed.

Is semaglutide a peptide?

Yes. Semaglutide is a synthetic peptide — a modified version of the natural GLP-1 hormone. It consists of 31 amino acids (the same as natural GLP-1) with modifications that extend its half-life from minutes to approximately 1 week. This makes it suitable for once-weekly injection.

What's the difference between GLP-1 and GIP?

GLP-1 (glucagon-like peptide-1) primarily suppresses appetite, slows gastric emptying, and stimulates insulin release. GIP (glucose-dependent insulinotropic polypeptide) also stimulates insulin release but additionally acts on fat cells and may modulate GLP-1's nausea effects at the brainstem. Tirzepatide targets both receptors simultaneously, which appears to produce greater weight loss than GLP-1 agonism alone.

Can I get GLP-1 peptides without a prescription?

No. FDA-approved GLP-1 peptides (semaglutide, tirzepatide) require a prescription. During the drug shortage period (2022–2024), compounding pharmacies were permitted to produce compounded semaglutide and tirzepatide, but this access has been restricted as supplies normalized. Buying "research chemical" versions of these peptides from online vendors is both illegal and dangerous — the quality and dosing of unlicensed products cannot be verified.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results

Continue Reading

← Back to Peptide Therapy